EPF Acknowledgement of Financial Support in 2025
Funding Transparency (Jan - Dec 2025)
| % of total income | ||
| Membership income | 27,850.00 | |
| Membership fees | 27850.00 | 1.3% |
| EPF wishes to thank the European Commission / European Agencies for their support in 2024 in relation to EPF's role in the following projects | ||
| Public Contribution 2025 | % of total income | |
| TOTAL European Commission support to projects 2025 | 611,473.69 | |
| UNIFIED | 5,613.81 | 0.3% |
| OHAMR | 11,538.53 | 0.5% |
| EDiTHA | 45,380.94 | 2.1% |
| EUCAPA | 4,086.83 | 0.2% |
| IMMUCAN | 21,490.98 | 1.0% |
| EU-PROACT | 75,663.68 | 3.5% |
| ENKORE | 9,498.41 | 0.4% |
| READI | 89,876.83 | 4.1% |
| PROPHET | 11,063.96 | 0.5% |
| IDERHA | 80,920.88 | 3.7% |
| Project Gravitate Health | 51,697.63 | 2.4% |
| H2O | 119,033.16 | 5.4% |
| Immuniverse | 1,351.96 | 0.1% |
| HEU EFS | 84,256.09 | 3.8% |
| EPF wishes to thank the following donors for their support: | ||
| Contribution to Operations | % of total income | |
| Operational & Engagement - work plan & Capacity Building Programme 2025 | 753,951.50 | |
| Amgen (Europe) GmbH | 30,000.00 | 1.4% |
| AOP | 12,000.00 | 0.5% |
| AstraZeneca UK Limited | 30,000.00 | 1.4% |
| BRISTOL MYERS SQUIBB | 36,951.50 | 1.7% |
| Chiesi Farmaceutici | 25,000.00 | 1.1% |
| CSL Behring GmbH | 10,000.00 | 0.5% |
| Daiichi Sankyo Europe GmbH | 30,000.00 | 1.4% |
| Edwards Lifesciences SA | 25,000.00 | 1.1% |
| EFPIA | 10,000.00 | 0.5% |
| F. Hoffmann-La Roche Ltd | 50,000.00 | 2.3% |
| GlaxoSmithKline | 60,000.00 | 2.7% |
| H. Lundbeck A/S | 15,000.00 | 0.7% |
| Ins. La conférence Hippocrate | 50,000.00 | 2.3% |
| MEDICINES FOR EUROPE AISBL | 20,000.00 | 0.9% |
| Merck Healthcare KGaA | 40,000.00 | 1.8% |
| Novartis Pharma AG | 80,000.00 | 3.7% |
| Novo Nordisk Denmark A/S | 35,000.00 | 1.6% |
| NV Janssen Pharmaceutica | 50,000.00 | 2.3% |
| Pfizer Inc. | 40,000.00 | 1.8% |
| Regeneron Pharmaceuticals | 40,000.00 | 1.8% |
| Takeda Pharmaceuticals Interna | 30,000.00 | 1.4% |
| Ucb Biopharma Srl | 15,000.00 | 0.7% |
| Vertex | 20,000.00 | 0.9% |
| BAROMETER - CONGRESS - PEOF | 594,953.22 | |
| Contribution to the CBP and others | % of total income | |
| PEOF | 25,458.00 | |
| The Synergist Asbl | 25,458.00 | 1.2% |
| BAROMETER | 80,000.00 | |
| Arts et Techniques du progrès | 30,000.00 | 1.4% |
| Amgen (Europe) GmbH | 10,000.00 | 0.5% |
| F. Hoffmann-La Roche Ltd | 20,000.00 | 0.9% |
| Takeda Pharmaceuticals Interna | 20,000.00 | 0.9% |
| CONGRESS | 474,000.00 | |
| Aisbl Medtech Europe | 10,000.00 | 0.5% |
| Alexion Pharma | 20,000.00 | 0.9% |
| Alfasigma | 40,000.00 | 1.8% |
| Ares Trading | 10,000.00 | 0.5% |
| Boehringer Ingelheim Internati | 20,000.00 | 0.9% |
| BGP Products | 10,000.00 | 0.5% |
| Butterfly Network | 10,000.00 | 0.5% |
| Chiesi Farmaceutici | 12,000.00 | 0.5% |
| Edwards Lifesciences SA | 10,000.00 | 0.5% |
| ENT E FEDERATION EUROPEENNE D'ASSOC | 40,000.00 | 1.8% |
| Europese Vereniging Fabrikanten Van Zelfzorgge | 10,000.00 | 0.5% |
| F. Hoffmann-La Roche Ltd | 15,000.00 | 0.7% |
| Grunenthal | 5,000.00 | 0.2% |
| Intuitive Surgical Sàrl | 10,000.00 | 0.5% |
| NV Janssen Pharmaceutica | 20,000.00 | 0.9% |
| Msd Belgium Bv | 30,000.00 | 1.4% |
| Novartis Pharma AG | 20,000.00 | 0.9% |
| OM Pharma | 12,000.00 | 0.5% |
| Open Health Communications | 5,000.00 | 0.2% |
| Pfizer Inc. | 25,000.00 | 1.1% |
| Sandoz International | 10,000.00 | 0.5% |
| Sanofi | 20,000.00 | 0.9% |
| SERVIER AFFAIRES MEDICALES | 30,000.00 | 1.4% |
| Shionogi | 40,000.00 | 1.8% |
| Takeda Pharmaceuticals Interna | 20,000.00 | 0.9% |
| VERTEX PHARMACEUTICALS (EUROPE | 20,000.00 | 0.9% |
| Other income | 15,495.22 | |
| Honorarium | 15,495.22 | 0.7% |